New ghrelin agonist, HM01 alleviates constipation and L-dopa-delayed gastric emptying in 6-hydroxydopamine rat model of Parkinson's disease

Neurogastroenterology and Motility

Volumn 26, Issue 12, 2014, Pages 1771-1782

  Karasawa, H ^a   Pietra, C ^b   Giuliano, C ^b   Garcia Rubio, S ^c   Xu, X ^d   Yakabi, S ^a   Tache Y ^a   Wang, L ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Helsinn SA Lugano   (Switzerland)

^c Helsinn Therapeutics Inc ^*  (United States)

^d Challenge MediTech Company Ltd   (China)

Author keywords

6 hydroxydopamine; Constipation; Gastric emptying; Ghrelin agonist; L dopa; Parkinson's disease

Indexed keywords

ANTIPARKINSON AGENT; GHRELIN; LEVODOPA; OXIDOPAMINE;

AGONISTS; ANIMAL; BRAIN; COMPLICATION; CONSTIPATION; DRUG EFFECTS; GASTROINTESTINAL TRANSIT; IMMUNOHISTOCHEMISTRY; MALE; PARKINSONISM; RAT; SPRAGUE DAWLEY RAT;

ANIMALS; ANTIPARKINSON AGENTS; BRAIN; CONSTIPATION; GASTROINTESTINAL TRANSIT; GHRELIN; IMMUNOHISTOCHEMISTRY; LEVODOPA; MALE; OXIDOPAMINE; PARKINSONIAN DISORDERS; RATS; RATS, SPRAGUE-DAWLEY;

EID: 84911474231     PISSN: 13501925     EISSN: 13652982     Source Type: Journal    
DOI: 10.1111/nmo.12459     Document Type: Article

References (63)

1. Jost WH. Gastrointestinal dysfunction in Parkinson's Disease. J Neurol Sci 2010; 289: 69-73.
2. Sakakibara R, Kishi M, Ogawa E, Tateno F, Uchiyama T, Yamamoto T, Yamanishi T. Bladder, bowel, and sexual dysfunction in Parkinson's disease. Parkinsons Dis 2011; 2011: 924605.
3. Poewe W, Antonini A, Zijlmans JC, Burkhard PR, Vingerhoets F. Levodopa in the treatment of Parkinson's disease: an old drug still going strong. Clin Interv Aging 2010; 5: 229-38.
4. Robertson DR, Renwick AG, Macklin B, Jones S, Waller DG, George CF, Fleming JS. The influence of levodopa on gastric emptying in healthy elderly volunteers. Eur J Clin Pharmacol 1992; 42: 409-12.
5. Kurlan R, Rothfield KP, Woodward WR, Nutt JG, Miller C, Lichter D, Shoulson I. Erratic gastric emptying of levodopa may cause "random" fluctuations of parkinsonian mobility. Neurology 1988; 38: 419-21.
6. Meissner WG, Frasier M, Gasser T, Goetz CG, Lozano A, Piccini P, Obeso JA, Rascol O et al. Priorities in Parkinson's disease research. Nat Rev Drug Discov 2011; 10: 377-93.
7. Mizutani M, Atsuchi K, Asakawa A, Matsuda N, Fujimura M, Inui A, Kato I, Fujimiya M. Localization of acyl ghrelin- and des-acyl ghrelin-immunoreactive cells in the rat stomach and their responses to intragastric pH. Am J Physiol Gastrointest Liver Physiol 2009; 297: G974-80.
8. Gahete MD, Rincon-Fernandez D, Villa-Osaba A, Hormaechea-Agulla D, Ibanez-Costa A, Martinez-Fuentes AJ, Gracia-Navarro F, Castano JP et al. Ghrelin gene products, receptors, and GOAT enzyme: biological and pathophysiological insight. J Endocrinol 2014; 220: R1-24.
9. Trudel L, Tomasetto C, Rio MC, Bouin M, Plourde V, Eberling P, Poitras P. Ghrelin/motilin-related peptide is a potent prokinetic to reverse gastric postoperative ileus in rat. Am J Physiol Gastrointest Liver Physiol 2002; 282: G948-52.
10. Kitazawa T, De Smet B, Verbeke K, Depoortere I, Peeters TL. Gastric motor effects of peptide and non-peptide ghrelin agonists in mice in vivo and in vitro. Gut 2005; 54: 1078-84.
11. Levin F, Edholm T, Schmidt PT, Gryback P, Jacobsson H, Degerblad M, Hoybye C, Holst JJ et al. Ghrelin stimulates gastric emptying and hunger in normal-weight humans. J Clin Endocrinol Metab 2006; 91: 3296-302.
12. Avau B, Carbone F, Tack J, Depoortere I. Ghrelin signaling in the gut, its physiological properties, and therapeutic potential. Neurogastroenterol Motil 2013; 25: 720-32.
13. Ejskjaer N, Vestergaard ET, Hellstrom PM, Gormsen LC, Madsbad S, Madsen JL, Jensen TA, Pezzullo JC et al. Ghrelin receptor agonist (TZP-101) accelerates gastric emptying in adults with diabetes and symptomatic gastroparesis. Aliment Pharmacol Ther 2009; 29: 1179-87.
14. Wang L, Murphy NP, Stengel A, Goebel-Stengel M, St Pierre DH, Maidment NT, Tache Y. Ghrelin prevents levodopa-induced inhibition of gastric emptying and increases circulating levodopa in fasted rats. Neurogastroenterol Motil 2012; 24: e235-45.
15. Shimizu Y, Chang EC, Shafton AD, Ferens DM, Sanger GJ, Witherington J, Furness JB. Evidence that stimulation of ghrelin receptors in the spinal cord initiates propulsive activity in the colon of the rat. J Physiol 2006; 576: 329-38.
16. Shafton AD, Sanger GJ, Witherington J, Brown JD, Muir A, Butler S, Abberley L, Shimizu Y et al. Oral administration of a centrally acting ghrelin receptor agonist to conscious rats triggers defecation. Neurogastroenterol Motil 2009; 21: 71-7.
17. Pustovit RV, Callaghan B, Kosari S, Rivera LR, Thomas H, Brock JA, Furness JB. The mechanism of enhanced defecation caused by the ghrelin receptor agonist, ulimorelin. Neurogastroenterol Motil 2014; 26: 264-71.
18. Deumens R, Blokland A, Prickaerts J. Modeling Parkinson's disease in rats: an evaluation of 6-OHDA lesions of the nigrostriatal pathway. Exp Neurol 2002; 175: 303-17.
19. Duty S, Jenner P. Animal models of Parkinson's disease: a source of novel treatments and clues to the cause of the disease. Br J Pharmacol 2011; 164: 1357-91.
20. Bove J, Perier C. Neurotoxin-based models of Parkinson's disease. Neuroscience 2012; 211: 51-76.
21. Zheng LF, Wang ZY, Li XF, Song J, Hong F, Lian H, Wang Q, Feng XY et al. Reduced expression of choline acetyltransferase in vagal motoneurons and gastric motor dysfunction in a 6-OHDA rat model of Parkinson's disease. Brain Res 2011; 1420: 59-67.
22. Zhu HC, Zhao J, Luo CY, Li QQ. Gastrointestinal dysfunction in a Parkinson's disease rat model and the changes of dopaminergic, nitric oxidergic, and cholinergic neurotransmitters in myenteric plexus. J Mol Neurosci 2012; 47: 15-25.
23. Blandini F, Balestra B, Levandis G, Cervio M, Greco R, Tassorelli C, Colucci M, Faniglione M et al. Functional and neurochemical changes of the gastrointestinal tract in a rodent model of Parkinson's disease. Neurosci Lett 2009; 467: 203-7.
24. Deleu D, Ebinger G, Michotte Y. Clinical and pharmacokinetic comparison of oral and duodenal delivery of levodopa/carbidopa in patients with Parkinson's disease with a fluctuating response to levodopa. Eur J Clin Pharmacol 1991; 41: 453-8.
25. Decressac M, Mattsson B, Bjorklund A. Comparison of the behavioural and histological characteristics of the 6-OHDA and alpha-synuclein rat models of Parkinson's disease. Exp Neurol 2012; 235: 306-15.
26. Paxinos G, Watson C. The Rat Brain in Stereotaxic Coordinates, 6th edn. Orlando: Academic Press, 2007.
27. Carvalho MM, Campos FL, Coimbra B, Pego JM, Rodrigues C, Lima R, Rodrigues AJ, Sousa N et al. Behavioral characterization of the 6-hydroxidopamine model of Parkinson's disease and pharmacological rescuing of non-motor deficits. Mol Neurodegener 2013; 8: 14.
28. Wang L, Goebel-Stengel M, Stengel A, Wu SV, Ohning G, Tache Y. Comparison of CRF-immunoreactive neurons distribution in mouse and rat brains and selective induction of Fos in rat hypothalamic CRF neurons by abdominal surgery. Brain Res 2011; 1415: 34-46.
29. Gue M, Gleizes-Escala C, Del Rio-Lacheze C, Junien JL, Bueno L. Reversal of CRF- and dopamine-induced stimulation of colonic motility by CCK and igmesine (JO 1784) in the rat. Br J Pharmacol 1994; 111: 930-4.
30. Colucci M, Cervio M, Faniglione M, De AS, Pajoro M, Levandis G, Tassorelli C, Blandini F et al. Intestinal dysmotility and enteric neurochemical changes in a Parkinson's disease rat model. Auton Neurosci 2012; 169: 77-86.
31. Vegezzi G, Al HZ, Levandis G, Cerri S, Blandini F, Gnudi G, Miduri F, Blandizzi C et al. Radiological analysis of gastrointestinal dysmotility in a model of central nervous dopaminergic degeneration: comparative study with conventional in vivo techniques in the rat. J Pharmacol Toxicol Methods 2014; 70: 163-9.
32. Ueki A, Otsuka M. Life style risks of Parkinson's disease: association between decreased water intake and constipation. J Neurol 2004; 251(Suppl. 7): vII18-23.
33. Amato D, Muller CP, Badiani A. Increased drinking after intra-striatal injection of the dopamine D2/D3 receptor agonist quinpirole in the rat. Psychopharmacology 2012; 223: 457-63.
34. Heetun ZS, Quigley EM. Gastroparesis and Parkinson's disease: a systematic review. Parkinsonism Relat Disord 2012; 18: 433-40.
35. Greene JG, Noorian AR, Srinivasan S. Delayed gastric emptying and enteric nervous system dysfunction in the rotenone model of Parkinson's disease. Exp Neurol 2009; 218: 154-61.
36. Hardoff R, Sula M, Tamir A, Soil A, Front A, Badarna S, Honigman S, Giladi N. Gastric emptying time and gastric motility in patients with Parkinson's disease. Mov Disord 2001; 16: 1041-7.
37. Wang L, Mogami S, Karasawa H, Yamada C, Yakabi S, Yakabi K, Hattori T, Tache Y. Preventive effect of rikkunshito on gastric motor function inhibited by l-dopa in rats. Peptides 2014; 55: 136-44.
38. Sanger GJ. Ghrelin and motilin receptor agonists: time to introduce bias into drug design. Neurogastroenterol Motil 2014; 26: 149-55.
39. Lasseter KC, Shaughnessy L, Cummings D, Pezzullo JC, Wargin W, Gagnon R, Oliva J, Kosutic G. Ghrelin agonist (TZP-101): safety, pharmacokinetics and pharmacodynamic evaluation in healthy volunteers: a phase I, first-in-human study. J Clin Pharmacol 2008; 48: 193-202.
40. Wargin W, Thomas H, Clohs L, St-Louis C, Ejskjaer N, Gutierrez M, Shaughnessy L, Kosutic G. Contribution of protein binding to the pharmacokinetics of the ghrelin receptor agonist TZP-101 in healthy volunteers and adults with symptomatic gastroparesis: two randomized, double-blind studies and a binding profile study. Clin Drug Investig 2009; 29: 409-18.
41. Fraser GL, Hoveyda HR, Tannenbaum GS. Pharmacological demarcation of the growth hormone, gut motility and feeding effects of ghrelin using a novel ghrelin receptor agonist. Endocrinology 2008; 149: 6280-8.
42. Fraser GL, Venkova K, Hoveyda HR, Thomas H, Greenwood-Van MB. Effect of the ghrelin receptor agonist TZP-101 on colonic transit in a rat model of postoperative ileus. Eur J Pharmacol 2009; 604: 132-7.
43. Tolle V, Zizzari P, Tomasetto C, Rio MC, Epelbaum J, Bluet-Pajot MT. In vivo and in vitro effects of ghrelin/motilin-related peptide on growth hormone secretion in the rat. Neuroendocrinology 2001; 73: 54-61.
44. Camina JP, Carreira MC, El Messari S, Llorens-Cortes C, Smith RG, Casanueva FF. Desensitization and endocytosis mechanisms of ghrelin-activated growth hormone secretagogue receptor 1a. Endocrinology 2004; 145: 930-40.
45. Date Y, Murakami N, Toshinai K, Matsukura S, Niijima A, Matsuo H, Kangawa K, Nakazato M. The role of the gastric afferent vagal nerve in ghrelin-induced feeding and growth hormone secretion in rats. Gastroenterology 2002; 123: 1120-8.
46. Dass NB, Munonyara M, Bassil AK, Hervieu GJ, Osbourne S, Corcoran S, Morgan M, Sanger GJ. Growth hormone secretagogue receptors in rat and human gastrointestinal tract and the effects of ghrelin. Neuroscience 2003; 120: 443-53.
47. Bron R, Yin L, Russo D, Furness JB. Expression of the ghrelin receptor gene in neurons of the medulla oblongata of the rat. J Comp Neurol 2013; 521: 2680-702.
48. Poitras P, Tomasetto C. The potential of ghrelin as a prokinetic. Regul Pept 2009; 155: 24-7.
49. Hirayama H, Shiina T, Shima T, Kuramoto H, Takewaki T, Furness B, Shimizu Y. Contrasting effects of ghrelin and des-acyl ghrelin on the lumbo-sacral defecation center and regulation of colorectal motility in rats. Neurogastroenterol Motil 2010; 22: 1124-31.
50. Ferens DM, Habgood MD, Saunders NR, Tan YH, Brown DJ, Brock JA, Furness JB. Stimulation of defecation in spinal cord-injured rats by a centrally acting ghrelin receptor agonist. Spinal Cord 2011; 49: 1036-41.
51. Furness JB, Cho HJ, Hunne B, Hirayama H, Callaghan BP, Lomax AE, Brock JA. Identification of neurons that express ghrelin receptors in autonomic pathways originating from the spinal cord. Cell Tissue Res 2012; 348: 397-405.
52. Tebbe JJ, Pasat IR, Monnikes H, Ritter M, Kobelt P, Schafer MK. Excitatory stimulation of neurons in the arcuate nucleus initiates central CRF-dependent stimulation of colonic propulsion in rats. Brain Res 2005; 1036: 130-8.
53. Wang L, Saint-Pierre DH, Tache Y. Peripheral ghrelin selectively increases Fos expression in neuropeptide Y - synthesizing neurons in mouse hypothalamic arcuate nucleus. Neurosci Lett 2002; 325: 47-51.
54. Kohno D, Yada T. Arcuate NPY neurons sense and integrate peripheral metabolic signals to control feeding. Neuropeptides 2012; 46: 315-9.
55. Tebbe JJ, Mronga S, Tebbe CG, Ortmann E, Arnold R, Schafer MK. Ghrelin-induced stimulation of colonic propulsion is dependent on hypothalamic neuropeptide Y1- and corticotrophin-releasing factor 1 receptor activation. J Neuroendocrinol 2005; 17: 570-6.
56. Dickson SL, Luckman SM. Induction of c-fos messenger ribonucleic acid in neuropeptide Y and growth hormone (GH)-releasing factor neurons in the rat arcuate nucleus following systemic injection of the GH secretagogue, GH-releasing peptide-6. Endocrinology 1997; 138: 771-7.
57. Hewson AK, Tung LY, Connell DW, Tookman L, Dickson SL. The rat arcuate nucleus integrates peripheral signals provided by leptin, insulin, and a ghrelin mimetic. Diabetes 2002; 51: 3412-9.
58. Cloud LJ, Greene JG. Gastrointestinal features of Parkinson's disease. Curr Neurol Neurosci Rep 2011; 11: 379-84.
59. Hewson AK, Dickson SL. Systemic administration of ghrelin induces Fos and Egr-1 proteins in the hypothalamic arcuate nucleus of fasted and fed rats. J Neuroendocrinol 2000; 12: 1047-9.
60. Schwartz MW, Woods SC, Porte D Jr, Seeley RJ, Baskin DG. Central nervous system control of food intake. Nature 2000; 404: 661-71.
61. Johnson RF, Johnson AK. Meal-related and rhythmic drinking: effects of abolition of rat's eating rhythm. Am J Physiol 1991; 261: R14-9.
62. Fitzsimons TJ, Le MJ. Eating as a regulatory control of drinking in the rat. J Comp Physiol Psychol 1969; 67: 273-83.
63. Hashimoto H, Fujihara H, Kawasaki M, Saito T, Shibata M, Otsubo H, Takei Y, Ueta Y. Centrally and peripherally administered ghrelin potently inhibits water intake in rats. Endocrinology 2007; 148: 1638-47.